Seeking Alpha

dpk

dpk
Send Message
View as an RSS Feed
View dpk's Comments BY TICKER:
Latest  |  Highest rated
  • Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So [View article]
    A SURVEY
    There is a saying,only bearer knows where Pen injection pinches.
    So a question to new entrant( to SA family),David Lille and other friends who have not felt the pinch themselves,while finding relatives taking insulin pen injection at dining table.
    Question is,hypothetically,but for better understanding of matter,in case before you could read first article on SA every day in the morning, you need to take an injection (which is reimbursable) or an inhaler which is not reimbursable which option would you prefer.
    I guess answer will be 0:60 and 40 deciding not to read SA at all.
    Having said that 40 also is unutlised afreeza mkt once it is found it is also reimbursable,because knowing its cost benefits in the long run insurance companies cannot afford not to insure it and pre diabetics will like to prevent it.
    Apr 6 07:33 PM | Likes Like |Link to Comment
  • Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So [View article]
    What %ge of portfolio just to compare your strong conviction with that of mine.
    Apr 6 05:39 PM | Likes Like |Link to Comment
  • MannKind: Follow The Smart Money [View article]
    Where would I be able to read the transcript of April 1st Adcom or hear the whole day proceedings, George? I followed Adcom on Adam's blog but would like to go thro the discussions in detail to understand the general thoughwave of Panel members and any specific concerns raised. Also was curious to see where that 2/10 confidence vote came from. thx
    Apr 6 05:03 PM | Likes Like |Link to Comment
  • Reconciling Rival Views Of Afrezza, And How To Play The Post-AdCom Surge [View article]
    Where would I be able to read the transcript of April 1st Adcom or hear the whole day proceedings, Jeff? I followed Adcom on Adam's blog but would like to go thro the discussions in detail to understand the general thoughwave of Panel members and any specific concerns raised. Also was curious to see where that 2/10 confidence vote came from. thx
    Apr 6 05:01 PM | Likes Like |Link to Comment
  • Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So [View article]
    What I meant by "on the go " is for carrying and traveling convenience, David.

    Also where can we read the transcript of April 1st Adcom or listen to the proceedings? I read the news item on Summer Street which mentions the 2/10 point. Going thro the transcript would help in understanding Adcom Panel's thoughts on discussion questions and any other points raised.
    Apr 6 03:13 AM | 1 Like Like |Link to Comment
  • Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So [View article]
    And we should also not ignore the fact that no specific storage conditions or refrigeration is required too which makes it easy to use on the go.
    Apr 6 02:54 AM | 2 Likes Like |Link to Comment
  • Will The Third Time Be A Charm For MannKind? Leading Fund Managers Definitely Think So [View article]
    Article says that rating of 2/10 is based on concern that Afrezza is inferior to injectable insulin in controlling blood glucose.
    Even if it is, maybe two puffs would be needed instead of one! But the HUGE convenience factor can not be ignored which would increase compliance resulting in better management of both T1 and T2, and less long-term harmful effects on various organs.
    Ipad maynot be able to do everything what a Desktop might thought see the ease of use with quite close practicality as a device.
    Apr 6 02:25 AM | 1 Like Like |Link to Comment
  • How MannKind Shows Depth Of The Diabetes Market [View article]
    MCA.Hats off for your superb Jan article on mnkd.I am gradually finishing reading that now with full respect and not to miss the depth.
    Apr 3 11:42 PM | Likes Like |Link to Comment
  • Reconciling Rival Views Of Afrezza, And How To Play The Post-AdCom Surge [View article]
    Thanks, Jeff, for consolidating all the thoughts in the tabular form which is really helpful. And I agree with your investment strategy as I had same thoughts yesterday after seeing the after-market move. Good feeling to be associated with great minds, like YOU. That's why there is a very meaningful saying, " One should always be surrounded by Experts."
    Apr 2 12:22 PM | 1 Like Like |Link to Comment
  • Why Millennium Healthcare Shares Will Continue To Rise [View article]
    Thanks author.It was a great call.An innovative company and a win win idea for all the participants.My position at one time today doubled in 3 working days.I hope you recommend to hold it for a very long term.
    Apr 2 02:52 AM | Likes Like |Link to Comment
  • What The FDA Document Says About Afrezza: Implications For FDA Approval [View article]
    Thanks for all your input Jeff in commenting for other articles too!.
    14-0 and 13-1 is awesome win for all the Diabetics and their families. thx for your contribution and George Rho's too.
    Apr 1 05:09 PM | Likes Like |Link to Comment
  • MannKind's Latest Critic: The FDA Has Joined The Chorus Of Missing Data Concerns [View article]
    I pray all those who were writing articles to short ( but conscious wise felt otherwise) never suffer from such a disease.
    Good luck to all.
    And to all longs who %ge portfolio wise are highly invested,be consoled that they are not alone.
    Mar 31 04:13 PM | 1 Like Like |Link to Comment
  • MannKind's Latest Critic: The FDA Has Joined The Chorus Of Missing Data Concerns [View article]
    "The composition of an advisory committee is not one in which the petitioning party has any input. For this reason alone, they aren't juries, screened to achieve impartiality, weighing the issues surrounding a claim. Rather, each panel is charged to act on behalf of the agency. This roundtable will be chaired by Dr. Robert J. Smith, and is comprised of specialists in the field of endocrinology.

    Please keep in mind that according to MannKind, these committee members will selflessly be voting against their own material interests on Tuesday afternoon. This because Afrezza's lesser risk of hypoglycemic events and weight-neutrality will keep patients in the care of general practitioners longer, without requiring them to switch over to the care of specialists, as they now tend to do."

    These two paragraphs of Author cast a shadow on the conduct of the Adcom members. Technically, they may not be jurors but thay have a similar role for all the practical purposes. They are supposed to be looking at the risk vs benefit of the treatment for the disease and the patients and that's what they will do. Yes, they will be guided by the questions posed to them by FDA but their decision WILL be based on the facts before them. When anybody is put in a situation where they are held responsible for the outcome, every sane person will follow their conscious and be a JUROR.
    Mar 31 02:27 PM | Likes Like |Link to Comment
  • MannKind's Latest Critic: The FDA Has Joined The Chorus Of Missing Data Concerns [View article]
    Agree about 2nd CRL, balert2 and thanks for the reminder about that FDA employee. After seeing your comment, I remebered the whole situation and the employee going to prison.
    Mar 31 02:15 PM | Likes Like |Link to Comment
  • What The FDA Document Says About Afrezza: Implications For FDA Approval [View article]
    Good points here, Thierry humblet that Perfect drugs DONOT exist and its always going to be benefits/risks balance to look at. thx
    Mar 29 01:47 PM | 1 Like Like |Link to Comment
COMMENTS STATS
314 Comments
239 Likes